Global Adalimumab Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Adalimumab market size was valued at USD 150.2 million in 2023 and is forecast to a readjusted size of USD 201.8 million by 2030 with a CAGR of 4.3% during review period.
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab's patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.
The Global Info Research report includes an overview of the development of the Adalimumab industry chain, the market status of Adults (Adalimumab, Adalimumab Biosimilar), Children (Adalimumab, Adalimumab Biosimilar), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Adalimumab.
Regionally, the report analyzes the Adalimumab markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Adalimumab market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Adalimumab market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Adalimumab industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Adalimumab, Adalimumab Biosimilar).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Adalimumab market.
Regional Analysis: The report involves examining the Adalimumab market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Adalimumab market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Adalimumab:
Company Analysis: Report covers individual Adalimumab manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Adalimumab This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Adults, Children).
Technology Analysis: Report covers specific technologies relevant to Adalimumab. It assesses the current state, advancements, and potential future developments in Adalimumab areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Adalimumab market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Adalimumab market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Adalimumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab, with price, sales, revenue and global market share of Adalimumab from 2019 to 2024.
Chapter 3, the Adalimumab competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Adalimumab market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab.
Chapter 14 and 15, to describe Adalimumab sales channel, distributors, customers, research findings and conclusion.
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab's patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.
The Global Info Research report includes an overview of the development of the Adalimumab industry chain, the market status of Adults (Adalimumab, Adalimumab Biosimilar), Children (Adalimumab, Adalimumab Biosimilar), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Adalimumab.
Regionally, the report analyzes the Adalimumab markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Adalimumab market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Adalimumab market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Adalimumab industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Adalimumab, Adalimumab Biosimilar).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Adalimumab market.
Regional Analysis: The report involves examining the Adalimumab market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Adalimumab market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Adalimumab:
Company Analysis: Report covers individual Adalimumab manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Adalimumab This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Adults, Children).
Technology Analysis: Report covers specific technologies relevant to Adalimumab. It assesses the current state, advancements, and potential future developments in Adalimumab areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Adalimumab market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Adalimumab market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Adalimumab
- Adalimumab Biosimilar
- Adults
- Children
- AbbVie
- Amgen
- Sandoz
- Boehringer Ingelheim
- Mylan
- Biogen
- Aark Pharmaceuticals
- Amgevita
- Delphis Pharma
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Adalimumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab, with price, sales, revenue and global market share of Adalimumab from 2019 to 2024.
Chapter 3, the Adalimumab competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Adalimumab market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab.
Chapter 14 and 15, to describe Adalimumab sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Adalimumab
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Adalimumab
1.3.3 Adalimumab Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Adults
1.4.3 Children
1.5 Global Adalimumab Market Size & Forecast
1.5.1 Global Adalimumab Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Adalimumab Sales Quantity (2019-2030)
1.5.3 Global Adalimumab Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Adalimumab Product and Services
2.1.4 AbbVie Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 AbbVie Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Adalimumab Product and Services
2.2.4 Amgen Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Amgen Recent Developments/Updates
2.3 Sandoz
2.3.1 Sandoz Details
2.3.2 Sandoz Major Business
2.3.3 Sandoz Adalimumab Product and Services
2.3.4 Sandoz Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Sandoz Recent Developments/Updates
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Adalimumab Product and Services
2.4.4 Boehringer Ingelheim Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Boehringer Ingelheim Recent Developments/Updates
2.5 Mylan
2.5.1 Mylan Details
2.5.2 Mylan Major Business
2.5.3 Mylan Adalimumab Product and Services
2.5.4 Mylan Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Mylan Recent Developments/Updates
2.6 Biogen
2.6.1 Biogen Details
2.6.2 Biogen Major Business
2.6.3 Biogen Adalimumab Product and Services
2.6.4 Biogen Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Biogen Recent Developments/Updates
2.7 Aark Pharmaceuticals
2.7.1 Aark Pharmaceuticals Details
2.7.2 Aark Pharmaceuticals Major Business
2.7.3 Aark Pharmaceuticals Adalimumab Product and Services
2.7.4 Aark Pharmaceuticals Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Aark Pharmaceuticals Recent Developments/Updates
2.8 Amgevita
2.8.1 Amgevita Details
2.8.2 Amgevita Major Business
2.8.3 Amgevita Adalimumab Product and Services
2.8.4 Amgevita Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Amgevita Recent Developments/Updates
2.9 Delphis Pharma
2.9.1 Delphis Pharma Details
2.9.2 Delphis Pharma Major Business
2.9.3 Delphis Pharma Adalimumab Product and Services
2.9.4 Delphis Pharma Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Delphis Pharma Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ADALIMUMAB BY MANUFACTURER
3.1 Global Adalimumab Sales Quantity by Manufacturer (2019-2024)
3.2 Global Adalimumab Revenue by Manufacturer (2019-2024)
3.3 Global Adalimumab Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Adalimumab by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Adalimumab Manufacturer Market Share in 2023
3.4.2 Top 6 Adalimumab Manufacturer Market Share in 2023
3.5 Adalimumab Market: Overall Company Footprint Analysis
3.5.1 Adalimumab Market: Region Footprint
3.5.2 Adalimumab Market: Company Product Type Footprint
3.5.3 Adalimumab Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Adalimumab Market Size by Region
4.1.1 Global Adalimumab Sales Quantity by Region (2019-2030)
4.1.2 Global Adalimumab Consumption Value by Region (2019-2030)
4.1.3 Global Adalimumab Average Price by Region (2019-2030)
4.2 North America Adalimumab Consumption Value (2019-2030)
4.3 Europe Adalimumab Consumption Value (2019-2030)
4.4 Asia-Pacific Adalimumab Consumption Value (2019-2030)
4.5 South America Adalimumab Consumption Value (2019-2030)
4.6 Middle East and Africa Adalimumab Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Adalimumab Sales Quantity by Type (2019-2030)
5.2 Global Adalimumab Consumption Value by Type (2019-2030)
5.3 Global Adalimumab Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Adalimumab Sales Quantity by Application (2019-2030)
6.2 Global Adalimumab Consumption Value by Application (2019-2030)
6.3 Global Adalimumab Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Adalimumab Sales Quantity by Type (2019-2030)
7.2 North America Adalimumab Sales Quantity by Application (2019-2030)
7.3 North America Adalimumab Market Size by Country
7.3.1 North America Adalimumab Sales Quantity by Country (2019-2030)
7.3.2 North America Adalimumab Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Adalimumab Sales Quantity by Type (2019-2030)
8.2 Europe Adalimumab Sales Quantity by Application (2019-2030)
8.3 Europe Adalimumab Market Size by Country
8.3.1 Europe Adalimumab Sales Quantity by Country (2019-2030)
8.3.2 Europe Adalimumab Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Adalimumab Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Adalimumab Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Adalimumab Market Size by Region
9.3.1 Asia-Pacific Adalimumab Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Adalimumab Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Adalimumab Sales Quantity by Type (2019-2030)
10.2 South America Adalimumab Sales Quantity by Application (2019-2030)
10.3 South America Adalimumab Market Size by Country
10.3.1 South America Adalimumab Sales Quantity by Country (2019-2030)
10.3.2 South America Adalimumab Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Adalimumab Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Adalimumab Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Adalimumab Market Size by Country
11.3.1 Middle East & Africa Adalimumab Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Adalimumab Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Adalimumab Market Drivers
12.2 Adalimumab Market Restraints
12.3 Adalimumab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Adalimumab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab
13.3 Adalimumab Production Process
13.4 Adalimumab Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab Typical Distributors
14.3 Adalimumab Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Adalimumab
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Adalimumab
1.3.3 Adalimumab Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Adults
1.4.3 Children
1.5 Global Adalimumab Market Size & Forecast
1.5.1 Global Adalimumab Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Adalimumab Sales Quantity (2019-2030)
1.5.3 Global Adalimumab Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Adalimumab Product and Services
2.1.4 AbbVie Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 AbbVie Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Adalimumab Product and Services
2.2.4 Amgen Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Amgen Recent Developments/Updates
2.3 Sandoz
2.3.1 Sandoz Details
2.3.2 Sandoz Major Business
2.3.3 Sandoz Adalimumab Product and Services
2.3.4 Sandoz Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Sandoz Recent Developments/Updates
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Adalimumab Product and Services
2.4.4 Boehringer Ingelheim Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Boehringer Ingelheim Recent Developments/Updates
2.5 Mylan
2.5.1 Mylan Details
2.5.2 Mylan Major Business
2.5.3 Mylan Adalimumab Product and Services
2.5.4 Mylan Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Mylan Recent Developments/Updates
2.6 Biogen
2.6.1 Biogen Details
2.6.2 Biogen Major Business
2.6.3 Biogen Adalimumab Product and Services
2.6.4 Biogen Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Biogen Recent Developments/Updates
2.7 Aark Pharmaceuticals
2.7.1 Aark Pharmaceuticals Details
2.7.2 Aark Pharmaceuticals Major Business
2.7.3 Aark Pharmaceuticals Adalimumab Product and Services
2.7.4 Aark Pharmaceuticals Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Aark Pharmaceuticals Recent Developments/Updates
2.8 Amgevita
2.8.1 Amgevita Details
2.8.2 Amgevita Major Business
2.8.3 Amgevita Adalimumab Product and Services
2.8.4 Amgevita Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Amgevita Recent Developments/Updates
2.9 Delphis Pharma
2.9.1 Delphis Pharma Details
2.9.2 Delphis Pharma Major Business
2.9.3 Delphis Pharma Adalimumab Product and Services
2.9.4 Delphis Pharma Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Delphis Pharma Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ADALIMUMAB BY MANUFACTURER
3.1 Global Adalimumab Sales Quantity by Manufacturer (2019-2024)
3.2 Global Adalimumab Revenue by Manufacturer (2019-2024)
3.3 Global Adalimumab Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Adalimumab by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Adalimumab Manufacturer Market Share in 2023
3.4.2 Top 6 Adalimumab Manufacturer Market Share in 2023
3.5 Adalimumab Market: Overall Company Footprint Analysis
3.5.1 Adalimumab Market: Region Footprint
3.5.2 Adalimumab Market: Company Product Type Footprint
3.5.3 Adalimumab Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Adalimumab Market Size by Region
4.1.1 Global Adalimumab Sales Quantity by Region (2019-2030)
4.1.2 Global Adalimumab Consumption Value by Region (2019-2030)
4.1.3 Global Adalimumab Average Price by Region (2019-2030)
4.2 North America Adalimumab Consumption Value (2019-2030)
4.3 Europe Adalimumab Consumption Value (2019-2030)
4.4 Asia-Pacific Adalimumab Consumption Value (2019-2030)
4.5 South America Adalimumab Consumption Value (2019-2030)
4.6 Middle East and Africa Adalimumab Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Adalimumab Sales Quantity by Type (2019-2030)
5.2 Global Adalimumab Consumption Value by Type (2019-2030)
5.3 Global Adalimumab Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Adalimumab Sales Quantity by Application (2019-2030)
6.2 Global Adalimumab Consumption Value by Application (2019-2030)
6.3 Global Adalimumab Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Adalimumab Sales Quantity by Type (2019-2030)
7.2 North America Adalimumab Sales Quantity by Application (2019-2030)
7.3 North America Adalimumab Market Size by Country
7.3.1 North America Adalimumab Sales Quantity by Country (2019-2030)
7.3.2 North America Adalimumab Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Adalimumab Sales Quantity by Type (2019-2030)
8.2 Europe Adalimumab Sales Quantity by Application (2019-2030)
8.3 Europe Adalimumab Market Size by Country
8.3.1 Europe Adalimumab Sales Quantity by Country (2019-2030)
8.3.2 Europe Adalimumab Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Adalimumab Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Adalimumab Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Adalimumab Market Size by Region
9.3.1 Asia-Pacific Adalimumab Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Adalimumab Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Adalimumab Sales Quantity by Type (2019-2030)
10.2 South America Adalimumab Sales Quantity by Application (2019-2030)
10.3 South America Adalimumab Market Size by Country
10.3.1 South America Adalimumab Sales Quantity by Country (2019-2030)
10.3.2 South America Adalimumab Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Adalimumab Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Adalimumab Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Adalimumab Market Size by Country
11.3.1 Middle East & Africa Adalimumab Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Adalimumab Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Adalimumab Market Drivers
12.2 Adalimumab Market Restraints
12.3 Adalimumab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Adalimumab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab
13.3 Adalimumab Production Process
13.4 Adalimumab Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab Typical Distributors
14.3 Adalimumab Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Adalimumab Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Adalimumab Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Adalimumab Product and Services
Table 6. AbbVie Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. AbbVie Recent Developments/Updates
Table 8. Amgen Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Major Business
Table 10. Amgen Adalimumab Product and Services
Table 11. Amgen Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Amgen Recent Developments/Updates
Table 13. Sandoz Basic Information, Manufacturing Base and Competitors
Table 14. Sandoz Major Business
Table 15. Sandoz Adalimumab Product and Services
Table 16. Sandoz Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Sandoz Recent Developments/Updates
Table 18. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 19. Boehringer Ingelheim Major Business
Table 20. Boehringer Ingelheim Adalimumab Product and Services
Table 21. Boehringer Ingelheim Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Boehringer Ingelheim Recent Developments/Updates
Table 23. Mylan Basic Information, Manufacturing Base and Competitors
Table 24. Mylan Major Business
Table 25. Mylan Adalimumab Product and Services
Table 26. Mylan Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Mylan Recent Developments/Updates
Table 28. Biogen Basic Information, Manufacturing Base and Competitors
Table 29. Biogen Major Business
Table 30. Biogen Adalimumab Product and Services
Table 31. Biogen Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Biogen Recent Developments/Updates
Table 33. Aark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Aark Pharmaceuticals Major Business
Table 35. Aark Pharmaceuticals Adalimumab Product and Services
Table 36. Aark Pharmaceuticals Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Aark Pharmaceuticals Recent Developments/Updates
Table 38. Amgevita Basic Information, Manufacturing Base and Competitors
Table 39. Amgevita Major Business
Table 40. Amgevita Adalimumab Product and Services
Table 41. Amgevita Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Amgevita Recent Developments/Updates
Table 43. Delphis Pharma Basic Information, Manufacturing Base and Competitors
Table 44. Delphis Pharma Major Business
Table 45. Delphis Pharma Adalimumab Product and Services
Table 46. Delphis Pharma Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Delphis Pharma Recent Developments/Updates
Table 48. Global Adalimumab Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 49. Global Adalimumab Revenue by Manufacturer (2019-2024) & (USD Million)
Table 50. Global Adalimumab Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 51. Market Position of Manufacturers in Adalimumab, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 52. Head Office and Adalimumab Production Site of Key Manufacturer
Table 53. Adalimumab Market: Company Product Type Footprint
Table 54. Adalimumab Market: Company Product Application Footprint
Table 55. Adalimumab New Market Entrants and Barriers to Market Entry
Table 56. Adalimumab Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Adalimumab Sales Quantity by Region (2019-2024) & (K Units)
Table 58. Global Adalimumab Sales Quantity by Region (2025-2030) & (K Units)
Table 59. Global Adalimumab Consumption Value by Region (2019-2024) & (USD Million)
Table 60. Global Adalimumab Consumption Value by Region (2025-2030) & (USD Million)
Table 61. Global Adalimumab Average Price by Region (2019-2024) & (USD/Unit)
Table 62. Global Adalimumab Average Price by Region (2025-2030) & (USD/Unit)
Table 63. Global Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 64. Global Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 65. Global Adalimumab Consumption Value by Type (2019-2024) & (USD Million)
Table 66. Global Adalimumab Consumption Value by Type (2025-2030) & (USD Million)
Table 67. Global Adalimumab Average Price by Type (2019-2024) & (USD/Unit)
Table 68. Global Adalimumab Average Price by Type (2025-2030) & (USD/Unit)
Table 69. Global Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 70. Global Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 71. Global Adalimumab Consumption Value by Application (2019-2024) & (USD Million)
Table 72. Global Adalimumab Consumption Value by Application (2025-2030) & (USD Million)
Table 73. Global Adalimumab Average Price by Application (2019-2024) & (USD/Unit)
Table 74. Global Adalimumab Average Price by Application (2025-2030) & (USD/Unit)
Table 75. North America Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 76. North America Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 77. North America Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 78. North America Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 79. North America Adalimumab Sales Quantity by Country (2019-2024) & (K Units)
Table 80. North America Adalimumab Sales Quantity by Country (2025-2030) & (K Units)
Table 81. North America Adalimumab Consumption Value by Country (2019-2024) & (USD Million)
Table 82. North America Adalimumab Consumption Value by Country (2025-2030) & (USD Million)
Table 83. Europe Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 84. Europe Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 85. Europe Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 86. Europe Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 87. Europe Adalimumab Sales Quantity by Country (2019-2024) & (K Units)
Table 88. Europe Adalimumab Sales Quantity by Country (2025-2030) & (K Units)
Table 89. Europe Adalimumab Consumption Value by Country (2019-2024) & (USD Million)
Table 90. Europe Adalimumab Consumption Value by Country (2025-2030) & (USD Million)
Table 91. Asia-Pacific Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 92. Asia-Pacific Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 93. Asia-Pacific Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 94. Asia-Pacific Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 95. Asia-Pacific Adalimumab Sales Quantity by Region (2019-2024) & (K Units)
Table 96. Asia-Pacific Adalimumab Sales Quantity by Region (2025-2030) & (K Units)
Table 97. Asia-Pacific Adalimumab Consumption Value by Region (2019-2024) & (USD Million)
Table 98. Asia-Pacific Adalimumab Consumption Value by Region (2025-2030) & (USD Million)
Table 99. South America Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 100. South America Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 101. South America Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 102. South America Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 103. South America Adalimumab Sales Quantity by Country (2019-2024) & (K Units)
Table 104. South America Adalimumab Sales Quantity by Country (2025-2030) & (K Units)
Table 105. South America Adalimumab Consumption Value by Country (2019-2024) & (USD Million)
Table 106. South America Adalimumab Consumption Value by Country (2025-2030) & (USD Million)
Table 107. Middle East & Africa Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 108. Middle East & Africa Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 109. Middle East & Africa Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 110. Middle East & Africa Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 111. Middle East & Africa Adalimumab Sales Quantity by Region (2019-2024) & (K Units)
Table 112. Middle East & Africa Adalimumab Sales Quantity by Region (2025-2030) & (K Units)
Table 113. Middle East & Africa Adalimumab Consumption Value by Region (2019-2024) & (USD Million)
Table 114. Middle East & Africa Adalimumab Consumption Value by Region (2025-2030) & (USD Million)
Table 115. Adalimumab Raw Material
Table 116. Key Manufacturers of Adalimumab Raw Materials
Table 117. Adalimumab Typical Distributors
Table 118. Adalimumab Typical Customers
Table 1. Global Adalimumab Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Adalimumab Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Adalimumab Product and Services
Table 6. AbbVie Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. AbbVie Recent Developments/Updates
Table 8. Amgen Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Major Business
Table 10. Amgen Adalimumab Product and Services
Table 11. Amgen Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Amgen Recent Developments/Updates
Table 13. Sandoz Basic Information, Manufacturing Base and Competitors
Table 14. Sandoz Major Business
Table 15. Sandoz Adalimumab Product and Services
Table 16. Sandoz Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Sandoz Recent Developments/Updates
Table 18. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 19. Boehringer Ingelheim Major Business
Table 20. Boehringer Ingelheim Adalimumab Product and Services
Table 21. Boehringer Ingelheim Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Boehringer Ingelheim Recent Developments/Updates
Table 23. Mylan Basic Information, Manufacturing Base and Competitors
Table 24. Mylan Major Business
Table 25. Mylan Adalimumab Product and Services
Table 26. Mylan Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Mylan Recent Developments/Updates
Table 28. Biogen Basic Information, Manufacturing Base and Competitors
Table 29. Biogen Major Business
Table 30. Biogen Adalimumab Product and Services
Table 31. Biogen Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Biogen Recent Developments/Updates
Table 33. Aark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Aark Pharmaceuticals Major Business
Table 35. Aark Pharmaceuticals Adalimumab Product and Services
Table 36. Aark Pharmaceuticals Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Aark Pharmaceuticals Recent Developments/Updates
Table 38. Amgevita Basic Information, Manufacturing Base and Competitors
Table 39. Amgevita Major Business
Table 40. Amgevita Adalimumab Product and Services
Table 41. Amgevita Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Amgevita Recent Developments/Updates
Table 43. Delphis Pharma Basic Information, Manufacturing Base and Competitors
Table 44. Delphis Pharma Major Business
Table 45. Delphis Pharma Adalimumab Product and Services
Table 46. Delphis Pharma Adalimumab Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Delphis Pharma Recent Developments/Updates
Table 48. Global Adalimumab Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 49. Global Adalimumab Revenue by Manufacturer (2019-2024) & (USD Million)
Table 50. Global Adalimumab Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 51. Market Position of Manufacturers in Adalimumab, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 52. Head Office and Adalimumab Production Site of Key Manufacturer
Table 53. Adalimumab Market: Company Product Type Footprint
Table 54. Adalimumab Market: Company Product Application Footprint
Table 55. Adalimumab New Market Entrants and Barriers to Market Entry
Table 56. Adalimumab Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Adalimumab Sales Quantity by Region (2019-2024) & (K Units)
Table 58. Global Adalimumab Sales Quantity by Region (2025-2030) & (K Units)
Table 59. Global Adalimumab Consumption Value by Region (2019-2024) & (USD Million)
Table 60. Global Adalimumab Consumption Value by Region (2025-2030) & (USD Million)
Table 61. Global Adalimumab Average Price by Region (2019-2024) & (USD/Unit)
Table 62. Global Adalimumab Average Price by Region (2025-2030) & (USD/Unit)
Table 63. Global Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 64. Global Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 65. Global Adalimumab Consumption Value by Type (2019-2024) & (USD Million)
Table 66. Global Adalimumab Consumption Value by Type (2025-2030) & (USD Million)
Table 67. Global Adalimumab Average Price by Type (2019-2024) & (USD/Unit)
Table 68. Global Adalimumab Average Price by Type (2025-2030) & (USD/Unit)
Table 69. Global Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 70. Global Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 71. Global Adalimumab Consumption Value by Application (2019-2024) & (USD Million)
Table 72. Global Adalimumab Consumption Value by Application (2025-2030) & (USD Million)
Table 73. Global Adalimumab Average Price by Application (2019-2024) & (USD/Unit)
Table 74. Global Adalimumab Average Price by Application (2025-2030) & (USD/Unit)
Table 75. North America Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 76. North America Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 77. North America Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 78. North America Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 79. North America Adalimumab Sales Quantity by Country (2019-2024) & (K Units)
Table 80. North America Adalimumab Sales Quantity by Country (2025-2030) & (K Units)
Table 81. North America Adalimumab Consumption Value by Country (2019-2024) & (USD Million)
Table 82. North America Adalimumab Consumption Value by Country (2025-2030) & (USD Million)
Table 83. Europe Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 84. Europe Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 85. Europe Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 86. Europe Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 87. Europe Adalimumab Sales Quantity by Country (2019-2024) & (K Units)
Table 88. Europe Adalimumab Sales Quantity by Country (2025-2030) & (K Units)
Table 89. Europe Adalimumab Consumption Value by Country (2019-2024) & (USD Million)
Table 90. Europe Adalimumab Consumption Value by Country (2025-2030) & (USD Million)
Table 91. Asia-Pacific Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 92. Asia-Pacific Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 93. Asia-Pacific Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 94. Asia-Pacific Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 95. Asia-Pacific Adalimumab Sales Quantity by Region (2019-2024) & (K Units)
Table 96. Asia-Pacific Adalimumab Sales Quantity by Region (2025-2030) & (K Units)
Table 97. Asia-Pacific Adalimumab Consumption Value by Region (2019-2024) & (USD Million)
Table 98. Asia-Pacific Adalimumab Consumption Value by Region (2025-2030) & (USD Million)
Table 99. South America Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 100. South America Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 101. South America Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 102. South America Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 103. South America Adalimumab Sales Quantity by Country (2019-2024) & (K Units)
Table 104. South America Adalimumab Sales Quantity by Country (2025-2030) & (K Units)
Table 105. South America Adalimumab Consumption Value by Country (2019-2024) & (USD Million)
Table 106. South America Adalimumab Consumption Value by Country (2025-2030) & (USD Million)
Table 107. Middle East & Africa Adalimumab Sales Quantity by Type (2019-2024) & (K Units)
Table 108. Middle East & Africa Adalimumab Sales Quantity by Type (2025-2030) & (K Units)
Table 109. Middle East & Africa Adalimumab Sales Quantity by Application (2019-2024) & (K Units)
Table 110. Middle East & Africa Adalimumab Sales Quantity by Application (2025-2030) & (K Units)
Table 111. Middle East & Africa Adalimumab Sales Quantity by Region (2019-2024) & (K Units)
Table 112. Middle East & Africa Adalimumab Sales Quantity by Region (2025-2030) & (K Units)
Table 113. Middle East & Africa Adalimumab Consumption Value by Region (2019-2024) & (USD Million)
Table 114. Middle East & Africa Adalimumab Consumption Value by Region (2025-2030) & (USD Million)
Table 115. Adalimumab Raw Material
Table 116. Key Manufacturers of Adalimumab Raw Materials
Table 117. Adalimumab Typical Distributors
Table 118. Adalimumab Typical Customers
LIST OF FIGURES
Figure 1. Adalimumab Picture
Figure 2. Global Adalimumab Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Adalimumab Consumption Value Market Share by Type in 2023
Figure 4. Adalimumab Examples
Figure 5. Adalimumab Biosimilar Examples
Figure 6. Global Adalimumab Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 7. Global Adalimumab Consumption Value Market Share by Application in 2023
Figure 8. Adults Examples
Figure 9. Children Examples
Figure 10. Global Adalimumab Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global Adalimumab Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Adalimumab Sales Quantity (2019-2030) & (K Units)
Figure 13. Global Adalimumab Average Price (2019-2030) & (USD/Unit)
Figure 14. Global Adalimumab Sales Quantity Market Share by Manufacturer in 2023
Figure 15. Global Adalimumab Consumption Value Market Share by Manufacturer in 2023
Figure 16. Producer Shipments of Adalimumab by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 17. Top 3 Adalimumab Manufacturer (Consumption Value) Market Share in 2023
Figure 18. Top 6 Adalimumab Manufacturer (Consumption Value) Market Share in 2023
Figure 19. Global Adalimumab Sales Quantity Market Share by Region (2019-2030)
Figure 20. Global Adalimumab Consumption Value Market Share by Region (2019-2030)
Figure 21. North America Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East & Africa Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 27. Global Adalimumab Consumption Value Market Share by Type (2019-2030)
Figure 28. Global Adalimumab Average Price by Type (2019-2030) & (USD/Unit)
Figure 29. Global Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 30. Global Adalimumab Consumption Value Market Share by Application (2019-2030)
Figure 31. Global Adalimumab Average Price by Application (2019-2030) & (USD/Unit)
Figure 32. North America Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 33. North America Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 34. North America Adalimumab Sales Quantity Market Share by Country (2019-2030)
Figure 35. North America Adalimumab Consumption Value Market Share by Country (2019-2030)
Figure 36. United States Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 37. Canada Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 38. Mexico Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Europe Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 40. Europe Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 41. Europe Adalimumab Sales Quantity Market Share by Country (2019-2030)
Figure 42. Europe Adalimumab Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. France Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. United Kingdom Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. Russia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Italy Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Adalimumab Sales Quantity Market Share by Region (2019-2030)
Figure 51. Asia-Pacific Adalimumab Consumption Value Market Share by Region (2019-2030)
Figure 52. China Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Japan Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Korea Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. India Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Southeast Asia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Australia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. South America Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 59. South America Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 60. South America Adalimumab Sales Quantity Market Share by Country (2019-2030)
Figure 61. South America Adalimumab Consumption Value Market Share by Country (2019-2030)
Figure 62. Brazil Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. Argentina Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Middle East & Africa Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 65. Middle East & Africa Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 66. Middle East & Africa Adalimumab Sales Quantity Market Share by Region (2019-2030)
Figure 67. Middle East & Africa Adalimumab Consumption Value Market Share by Region (2019-2030)
Figure 68. Turkey Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Egypt Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Saudi Arabia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. South Africa Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Adalimumab Market Drivers
Figure 73. Adalimumab Market Restraints
Figure 74. Adalimumab Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Adalimumab in 2023
Figure 77. Manufacturing Process Analysis of Adalimumab
Figure 78. Adalimumab Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
Figure 1. Adalimumab Picture
Figure 2. Global Adalimumab Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Adalimumab Consumption Value Market Share by Type in 2023
Figure 4. Adalimumab Examples
Figure 5. Adalimumab Biosimilar Examples
Figure 6. Global Adalimumab Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 7. Global Adalimumab Consumption Value Market Share by Application in 2023
Figure 8. Adults Examples
Figure 9. Children Examples
Figure 10. Global Adalimumab Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global Adalimumab Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Adalimumab Sales Quantity (2019-2030) & (K Units)
Figure 13. Global Adalimumab Average Price (2019-2030) & (USD/Unit)
Figure 14. Global Adalimumab Sales Quantity Market Share by Manufacturer in 2023
Figure 15. Global Adalimumab Consumption Value Market Share by Manufacturer in 2023
Figure 16. Producer Shipments of Adalimumab by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 17. Top 3 Adalimumab Manufacturer (Consumption Value) Market Share in 2023
Figure 18. Top 6 Adalimumab Manufacturer (Consumption Value) Market Share in 2023
Figure 19. Global Adalimumab Sales Quantity Market Share by Region (2019-2030)
Figure 20. Global Adalimumab Consumption Value Market Share by Region (2019-2030)
Figure 21. North America Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East & Africa Adalimumab Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 27. Global Adalimumab Consumption Value Market Share by Type (2019-2030)
Figure 28. Global Adalimumab Average Price by Type (2019-2030) & (USD/Unit)
Figure 29. Global Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 30. Global Adalimumab Consumption Value Market Share by Application (2019-2030)
Figure 31. Global Adalimumab Average Price by Application (2019-2030) & (USD/Unit)
Figure 32. North America Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 33. North America Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 34. North America Adalimumab Sales Quantity Market Share by Country (2019-2030)
Figure 35. North America Adalimumab Consumption Value Market Share by Country (2019-2030)
Figure 36. United States Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 37. Canada Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 38. Mexico Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Europe Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 40. Europe Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 41. Europe Adalimumab Sales Quantity Market Share by Country (2019-2030)
Figure 42. Europe Adalimumab Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. France Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. United Kingdom Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. Russia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Italy Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Adalimumab Sales Quantity Market Share by Region (2019-2030)
Figure 51. Asia-Pacific Adalimumab Consumption Value Market Share by Region (2019-2030)
Figure 52. China Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Japan Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Korea Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. India Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Southeast Asia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Australia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. South America Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 59. South America Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 60. South America Adalimumab Sales Quantity Market Share by Country (2019-2030)
Figure 61. South America Adalimumab Consumption Value Market Share by Country (2019-2030)
Figure 62. Brazil Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. Argentina Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Middle East & Africa Adalimumab Sales Quantity Market Share by Type (2019-2030)
Figure 65. Middle East & Africa Adalimumab Sales Quantity Market Share by Application (2019-2030)
Figure 66. Middle East & Africa Adalimumab Sales Quantity Market Share by Region (2019-2030)
Figure 67. Middle East & Africa Adalimumab Consumption Value Market Share by Region (2019-2030)
Figure 68. Turkey Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Egypt Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Saudi Arabia Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. South Africa Adalimumab Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Adalimumab Market Drivers
Figure 73. Adalimumab Market Restraints
Figure 74. Adalimumab Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Adalimumab in 2023
Figure 77. Manufacturing Process Analysis of Adalimumab
Figure 78. Adalimumab Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
More Publications
Global Transcatheter Aortic Valve Replacement (TAVR) Market 2026 by Company, Regions, Type and Application, Forecast to 2032
US$ 3,480.00
August 2026
94 pages
Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Dermatological Drugs Market 2018, Forecast to 2023
US$ 4,880.00
December 2018
131 pages
Global DHA Oil Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
US$ 3,480.00
April 2019
138 pages
Global Energy Management Systems for Healthcare Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
US$ 3,480.00
August 2018
136 pages
Global Pediatric Healthcare Service Market 2024 by Company, Regions, Type and Application, Forecast to 2030
US$ 3,480.00
October 2026
85 pages
